Ian Eliason

Trio Labs is pushing the boundaries of what’s possible in micro metal manufacturing. Our mission is to improve patients’ lives by enabling the next generation of medical devices. With Resin Infused Powder Lithography (RIPL), medical device manufacturers can now achieve a previously impossible combination of fine resolution, rapid production speed, and high complexity. RIPL technology allows for ultra-precise, on-demand solutions that meet the rigorous standards of MedTech applications with a seamless transition between prototype and production. Whether you need rapid iterations of a handful of custom metal parts or full-scale production runs of thousands of complex, intricate components, our proprietary technology produces net-shape micro scale parts with ultimate precision. The unmatched design flexibility of this new additive process makes it possible to create complex geometries that other technologies simply can’t achieve and imagine new possibilities for MedTech that were previously out of reach. Contact Trio Labs today to discover how our innovative process can reduce costs and manufacturing times for your existing products — or enable wholly new solutions. We produce parts across a wide range of medical device markets, from advanced surgical tools to interventional devices, microneedle arrays, miniaturized infusion pumps, and drug delivery systems. Join us in shaping the future of medical devices. Whether you’re in the early stages of development or already on the market, Trio Labs is your partner in innovation.

The future of single-use, column-free purification is here. We are dedicated to empowering biopharmaceutical manufacturers with our cutting-edge, columnless single-use continuous chromatography platform, offering enhanced flexibility, scalability, and purity, reducing downtime and resin consumption, and maximizing productivity for the cost-effective production of life-saving therapies. With more efficient process development, clinical manufacturing, and commercial manufacturing, we aim to help our customers provide the most affordable therapeutics possible to their patients. Join us for our virtual ChromaChats™ roundtables to discuss and solve challenges in the field of chromatography with other leaders, network with their peers, collaborate on projects, share successes and pitfalls, and connect with other leaders. Learn more here: https://chromatan.com/chromachats/

At BioROSA Technologies, we want to make the diagnosis of Autism Spectrum disorder (ASD) rapid and simple.

Probius, is a deep-tech company bridging the data gap between biology and AI, thereby illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products

Reveal, based out of Montréal, Quebec, has been helping surgeons for the past 6 years by giving them deeper, data-driven insights into the human tissues they encounter through Reveals AI-enabled optical detection systems for tumor margin assessment and tissue characterization. Reveals technology, specifically The Sentry System, uses the Raman Effect to help surgeons safely and precisely remove more cancer than current imaging modalities.

HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.

Optina’s Retinal Deep Phenotyping platform addresses the major challenges faced by the healthcare system related to an aging population.   Recently, Optina was granted breakthrough device designation by the FDA for our first indication in Alzheimer’s Disease detection which enables a dramatic improvement in the diagnostic accuracy of dementia.   Our ecosystem comprised of a proprietary platform and a network of eye clinics creates a new and efficient means for simple patient stratification. The ecosystem allows for the collection of data rich retinal images with 30X more information than current retinal imaging platforms.   Algorithm development utilizes a ground truth that is based on specifically characterized patients from leading institutions around the world.   With our developing product pipeline, Optina continues to bring clarity and accessibility to early stage diagnosis, improving the life of millions.

NOTICE: Please visit our website for any current job opportunities. Innovein has not and will not post job opportunities on LinkedIn. Over 10% of the US/EU suffers from bad valves in the veins of legs and advanced vein disease, with no option for valve replacement. Innovein, a Y Combinator and VC backed medical device company, addresses this unmet medical need with a first-in-class replacement valve for veins. Innovein has been awarded by Forbes, the Medical Device and Diagnostic Industry, MIT (CHIEF), and many others. In aggregate, the founding team of three has invented and brought over 15 medical devices to market, selling over $3B. They are addressing the multi-billion dollar unmet need of vein disease and successfully oversubscribed target financing. Awards: Forbes 30 under 30 - from over 15,000 nominations Innovation Award of the Year - Award rate < 4% - UCSF Rosenman Institute MIT (CHIEF) Business Competition - Diamond Award Recipient - Over 200 applicants Giant Partners'​ Top 100 Startups Winner - AIM startup competition and Angellist Prize Medtech's Rising Star - Medical Device and Diagnostic Industry #1 Top Trending Deal - Angellist July 2016 #1 Top Listed Company on Angellist June 2017 (From over 3,000,000 companies) Accelerators: Y Combinator - Acceptance rate < 2% StartX Med - Acceptance rate < 8% For more information about Innovein email: info (at) innoveinmedical (dot) com

Juno Diagnostics supports growing families and their providers through every step of the pregnancy journey. Our expert team of scientists is developing the next generation of accessible and affordable prenatal screening assays based on cell-free DNA to empower families with science from the start. *COMMERCIAL OPERATIONS PERMANENTLY CLOSED*

Trio Labs is pushing the boundaries of what’s possible in micro metal manufacturing. Our mission is to improve patients’ lives by enabling the next generation of medical devices. With Resin Infused Powder Lithography (RIPL), medical device manufacturers can now achieve a previously impossible combination of fine resolution, rapid production speed, and high complexity. RIPL technology allows for ultra-precise, on-demand solutions that meet the rigorous standards of MedTech applications with a seamless transition between prototype and production. Whether you need rapid iterations of a handful of custom metal parts or full-scale production runs of thousands of complex, intricate components, our proprietary technology produces net-shape micro scale parts with ultimate precision. The unmatched design flexibility of this new additive process makes it possible to create complex geometries that other technologies simply can’t achieve and imagine new possibilities for MedTech that were previously out of reach. Contact Trio Labs today to discover how our innovative process can reduce costs and manufacturing times for your existing products — or enable wholly new solutions. We produce parts across a wide range of medical device markets, from advanced surgical tools to interventional devices, microneedle arrays, miniaturized infusion pumps, and drug delivery systems. Join us in shaping the future of medical devices. Whether you’re in the early stages of development or already on the market, Trio Labs is your partner in innovation.

The future of single-use, column-free purification is here. We are dedicated to empowering biopharmaceutical manufacturers with our cutting-edge, columnless single-use continuous chromatography platform, offering enhanced flexibility, scalability, and purity, reducing downtime and resin consumption, and maximizing productivity for the cost-effective production of life-saving therapies. With more efficient process development, clinical manufacturing, and commercial manufacturing, we aim to help our customers provide the most affordable therapeutics possible to their patients. Join us for our virtual ChromaChats™ roundtables to discuss and solve challenges in the field of chromatography with other leaders, network with their peers, collaborate on projects, share successes and pitfalls, and connect with other leaders. Learn more here: https://chromatan.com/chromachats/

Zoic Capital is the only US-based venture firm focused on early stage healthcare innovations at the intersection of life sciences and medical technology. Promising Scientific Advancements: We look for breakthroughs with the potential for broad IP and commercial-ready maturity. We invest in roadmaps that leverage a core innovation across many applications and industries. Focus on Life Sciences: We see the most exciting advancements coming from life sciences labs, becoming tools that maintain and treat our health. We look at both technologies that enable development and care delivery devices. We Follow the Numbers: We follow our gut, but we also reinforce each of our decisions with numbers. We believe that merging qualitative and quantitative analysis is the best way to make successful investment decisions. Mentored Capital: We have the skills, experience and network to help, working closely with select teams to transform research into high impact, market-ready products. Milestone-Based Investing: We craft unique deal structures for each portfolio company based on mutually defined milestones. We find this approach creates ongoing momuntum and sets us all up for success.

At BioROSA Technologies, we want to make the diagnosis of Autism Spectrum disorder (ASD) rapid and simple.

Probius, is a deep-tech company bridging the data gap between biology and AI, thereby illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products